Ocumension Therapeutics 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-21 6:21 pm Purchase | 2020-12-31 | 13D | EyePoint Pharmaceuticals, Inc. EYPT | Ocumension Therapeutics | 3,010,722 16.600% | 3,010,722 (New Position) | Filing |